Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Combidex Lymph Node Imaging Data Insufficient For Approval, FDA Cmte. Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Committee votes data are insufficient to support Advanced Magnetics' request for broad indication of detecting metastatic lymph nodes in various cancers. Members cite trial design and deficiencies in primary efficacy analysis.

You may also be interested in...



Advanced Magnetics' Combidex "Approvable" Letter Requests More Efficacy Data

The decision follows the Oncologic Drugs Advisory Committee vote that current data do not support approval of the imaging agent for the proposed indication. FDA suggested that the data be "limited to a well-defined population of specific cancer types," the company says.

FDA Antihypertensive Draft Class Labeling To Be Reviewed By Cardio-Renal Committee

FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.

Topics

UsernamePublicRestriction

Register

PS061863

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel